Drug Profile
Research programme: Parkinson's disease therapies - Berg Pharma/Parkinson's Institute and Clinical Center
Latest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator Berg Pharma; The Parkinsons Institute and Clinical Center
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Parkinson's-disease(Diagnosis) in USA
- 16 Jul 2016 No recent reports of development identified for research development in Parkinson's-disease in USA
- 18 Feb 2014 Preclinical trials in Parkinson's disease (diagnosis) in USA (unspecified route)